Using AI and Retrosynthesis To Streamline Small Molecule Discovery
At the heart of our mission is a dedication to transforming drug discovery through innovation and collaboration. We’re building an integrated technology ecosystem - merging advanced AI decision tools with a global supply network of critical chemicals - to empower researchers to accelerate the journey from scientific discovery to therapeutic breakthroughs.
In this presentation, we’ll walk through an integrated digital Design–Make–Test–Analyze (DMTA) cycle using ADDISON™ for generative molecule design and predictive ADMET modelling, and SYNTHIA® for retrosynthetic and library synthesis planning. This iterative workflow enables faster decision-making, better compound prioritization, and closer alignment between design and synthesis.
Development of fully human antibodies to Her-2 domains and their applications as antibody drug conjugates.
Bridging Science and Strategy: Advancing Drug Discovery
Three lessons from building AI-first delivery for the software around the science.
The hidden reason AI adoption is accelerating while delivery results lag behind.
What separates successful AI-first teams from those stuck in endless experimentation.
How leading pharma and biotech organizations can scale software delivery around the science.